Sifalimumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameSifalimumab
Drug Alias Name西法木单抗Anti-IFNa MAb司法利木单抗sifalimumabumSifnalimumab +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterferon alpha inhibitors
TargetsInterferon alpha
Therapy Area/IndicationsPlaque psoriasisLupus Erythematosus, SystemicPolymyositis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcMedimmune Llc
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisLupus Erythematosus, SystemicPolymyositis +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG